SciELO - Scientific Electronic Library Online

 
vol.71 issue9BCerebrospinal fluid analysis in the context of CNS demyelinating diseasesCerebrospinal fluid analysis in infectious diseases of the nervous system: when to ask, what to ask, what to expect author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Arquivos de Neuro-Psiquiatria

Print version ISSN 0004-282XOn-line version ISSN 1678-4227

Abstract

ALMEIDA, Sergio Monteiro de. Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers. Arq. Neuro-Psiquiatr. [online]. 2013, vol.71, n.9B, pp.689-692. ISSN 0004-282X.  https://doi.org/10.1590/0004-282X20130152.

Cognitive impairment and major depressive disorder (MDD) are common HIV-1 central nervous system (CNS) complications. Their frequencies in AIDS patients are 36% and 45%, respectively. The diagnoses of HIV cognitive impairment are made by clinical criteria, no single laboratory test or biomarker establishes the diagnosis. Factors of indirect neuronal injury related with the pathophysiology of the HIV infection in the CNS, are the factors studied as biomarkers. In the present no biomarker is established to the diagnosis of HIV cognitive impairment, much still needs to be done. We review in this paper some biomarkers in cerebrospinal fluid that could be valuable to the diagnosis of HIV cognitive impairment. Diagnosing depression in the context of HIV can be challenging, to identify a biomarker that could help in the diagnosis would be very important, although MDD risks and neurobiology are still poorly understood.

Keywords : HIV dementia; major depressive disorder; central nervous system; HIV; cerebrospinal fluid; biomarkers; HIV demência; desordem depressiva maior; sistema nervoso central; HIV; líquido cefalorraquidiano; biomarcadores.

        · abstract in Portuguese     · text in English     · English ( pdf )